Assessing the transition from intravenous to subcutaneous delivery of rituximab: Benefits for payers, health care professionals, and patients with lymphoma

Subcutaneous (SC) administration of rituximab provides an opportunity for reduced patient treatment burden and increased healthcare efficiencies as an alternative to intravenous (IV) rituximab. There is minimal evidence comparing costs associated with SC and IV rituximab in a US setting. This resear...

Descripción completa

Detalles Bibliográficos
Autores principales: Harvey, Michael J., Zhong, Yi, Morris, Eric, Beverage, Jacob N., Epstein, Robert S., Chawla, Anita J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8786206/
https://www.ncbi.nlm.nih.gov/pubmed/35073335
http://dx.doi.org/10.1371/journal.pone.0261336

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8786206/
https://www.ncbi.nlm.nih.gov/pubmed/35073335
http://dx.doi.org/10.1371/journal.pone.0261336

Ejemplares similares